Product information and disease descriptionProduct descriptionProduct information
Product comparison
21 evidence topics · 15 sources
Deucrictibant: route, dose, and time to onset of symptom relief in RAPIDe-3
Deucrictibant: redosing and rescue medication in RAPIDe-3
Sebetralstat: route, dose, redosing, and time to beginning of symptom relief in KONFIDENT
Icatibant: route, dose, redosing, and time to symptom reduction in its placebo-controlled trial
Ecallantide: route, administration setting, redosing, and outcome measures in its two trials
Plasma-derived C1 esterase inhibitor: route, dose, and time to onset of relief in its placebo-controlled trial
Recombinant C1 esterase inhibitor: route, dose, redosing, and time to beginning of relief in its placebo-controlled trial
Cross-trial comparison with sebetralstat and icatibant as stated by the RAPIDe-3 investigators
Redosing and rescue medication with deucrictibant and sebetralstat as stated by the RAPIDe-3 investigators
Pharmacokinetics and potency of deucrictibant and icatibant as stated by the RAPIDe-3 investigators
Safety relative to icatibant as stated by the RAPIDe-3 investigators
Company statement: absence of head-to-head comparison with icatibant
Company statement: anticipated differentiation of the immediate-release capsule
Company statement: anticipated position relative to the current standard of care
Indirect comparison of sebetralstat with recombinant C1 esterase inhibitor funded by KalVista
“Based on a systematic literature review and feasibility assessment, only the pivotal trial for intravenous rhC1INH (NCT01188564) reported necessary data for a comparable primary efficacy endpoint (time to beginning of symptom relief) to enable an ITC with oral sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The fixed-effects model found no significant differences in time to beginning of symptom relief between sebetralstat 300 mg and rhC1INH 50 IU/kg (hazard ratio [95% credible interval], 0.96 [0.42–2.15] to 1.19 [0.58–2.45]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, the location of on-demand treatment administration differed, with the KONFIDENT trial being the first phase 3 trial to allow patients to treat at home; the impact of this difference cannot be assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was supported by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect comparison of recombinant C1 esterase inhibitor with sebetralstat funded by Pharming
“In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84–7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06–0.53) vs sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients in the rhC1-INH trials had a severe or very severe attack at baseline based on the PGI-S scale [3, 4], whereas patients enrolled in the KONFIDENT trial had a range of baseline attack severities, with only 17.5% of patients having severe or very severe attacks at baseline [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rhC1-INH trials required clinic visits for assessment and treatment, resulting in delayed rhC1-INH administration (median 242 min) [3, 4], whereas the KONFIDENT trial allowed for self-administration of sebetralstat (median 41 min) [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In these scenario analyses, the HRs for TTCR were 1.41 (95% CI 0.63–3.18) and 9.76 (95% CI 4.94–19.29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rapid Service and Open Access fees were funded by Pharming Healthcare, Inc., Warren, NJ, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methodological critique of the Pharming-funded indirect comparison
Health technology assessment appraisal of the sebetralstat indirect comparison
Cross-trial comparison caveats: guideline statement
“Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct comparisons among these options are limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events are limited to headache, nevertheless, long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cross-trial comparison caveats: infeasibility of a head-to-head trial
“Lastly, it is recognized that the ideal comparison between therapies would be a randomized, double-blind, head-to-head clinical trial (double dummy design).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in the context of HAE, there are multiple reasons making such an RCT infeasible, including challenges in aligning time to treatment for an oral versus an injectable treatment, and the ability to use a double-blind approach for evaluating oral versus injectable treatments, due to expected skin reactions with the latter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because no head-to-head trials have evaluated on-demand therapies for hereditary angioedema (HAE), variability in study designs and outcome definitions across clinical trials limits direct interpretation of relative efficacy, including time to complete resolution (TTCR) and the need for redosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral therapies developed for prophylaxis and on-demand treatment
“Over the past 6 years two oral therapies have been developed for HAE to include berotralstat for long term prophylaxis (LTP) and sebetralstat for on-demand therapy (ODT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Presently, deucrictibant, another oral HAE therapy, is under investigation and appears effective for LTP and ODT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote